← Leaderboards
Kathryn Elizabeth Uhrich
Rutgers The St Univ Of Nj New Brunswick
$4,572,851
Attributed
$7,902,384
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,902,384 · 7
By mechanism
R01$6,977,654 · 3
R21$867,110 · 2
R03$37,620 · 1
R13$20,000 · 1
Top collaborators
- Prabhas V Moghe5 shared
- J Patrick O'Connor5 shared
- John Ricci5 shared
- Michael Chikindas2 shared
- Hoda Gebril1 shared
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationBaseAnti-Inflammatory AgentsPolymersInflammatoryAnti-InflammatoryDrug Delivery SystemsLifeBiocompatible MaterialsDesignIn VitroSalicylateResearch PersonnelStructureVertebral ColumnHealedResponseProdrugsHealingInhibitor/AntagonistCostDoseBone RegenerationEsters
Grant awards (23)
Nanotechnology for Glial Targeting and Inhibition of Neuroinflammation for Alzheimerâs Disease$445,625
R21 · FY2024 · AG
Synthetic AMPs that Control Biofilms of Gram-variable Pathogens$191,884
R21 · FY2017 · AI
Synthetic AMPs that Control Biofilms of Gram-variable Pathogens$229,601
R21 · FY2016 · AI
Synthetic Counter-ligands for Inhibition of Atherosclerosis$528,094
R01 · FY2014 · HL
Synthetic Counter-ligands for Inhibition of Atherosclerosis$502,386
R01 · FY2013 · HL
Synthetic Counter-ligands for Inhibition of Atherosclerosis$613,682
R01 · FY2012 · HL
Local Modulation of Inflammation to Heal Cranial-facial Bone Defects$596,991
R01 · FY2012 · DE
Local Modulation of Inflammation to Heal Cranial-facial Bone Defects$25,368
R01 · FY2012 · DE
Local Modulation of Inflammation to Heal Cranial-facial Bone Defects$621,636
R01 · FY2011 · DE
Synthetic Counter-ligands for Inhibition of Atherosclerosis$614,782
R01 · FY2011 · HL
Local Modulation of Inflammation to Heal Cranial-facial Bone Defects$628,311
R01 · FY2010 · DE
Local Modulation of Inflammation to Heal Cranial-facial Bone Defects$666,047
R01 · FY2009 · DE
Biodegradable Polymeric Prodrugs$294,880
R01 · FY2009 · DE · contact PI
Biodegradable Polymeric Prodrugs$297,025
R01 · FY2008 · DE · contact PI
Biodegradable Polymeric Prodrugs$292,351
R01 · FY2007 · DE · contact PI
Biodegradable Polymeric Prodrugs$303,361
R01 · FY2006 · DE · contact PI
Biodegradable Polymeric Prodrugs$319,502
R01 · FY2005 · DE
Nanomaterials and the Environment$20,000
R13 · FY2005 · DE
BIODEGRADABLE POLYMERIC PRODRUGS$161,372
R01 · FY2003 · DE
BIODEGRADABLE POLYMERIC PRODRUGS$161,372
R01 · FY2002 · DE
BIODEGRADABLE POLYMERIC PRODRUGS$161,372
R01 · FY2001 · DE
BIODEGRADABLE POLYMERIC PRODRUGS$189,122
R01 · FY2000 · DE
POLYMERS WITH BIOACTIVE DEGRADATION PRODUCTS$37,620
R03 · FY2000 · DE